References
- Zhang J, Nichols KE, Downing JR. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2016;374(14):1391.
- Gut P, Komarowska H, Czarnywojtek A, et al. Familial syndromes associated with neuroendocrine tumours. Contemp Oncol (Pozn). 2015;19(3):176–83.
- Maher ER, Yates JR, Harries R, et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med. 1990;77:1151–1163.
- Giannini C, Scheithauer BW, Hellbusch LC, et al. Peripheral nerve hemangioblastoma. Mod Pathol. 1998;11(10):999–1004.
- Lonser RR, Butman JA, Huntoon K, et al. Prospective natural history study of central nervous system hemangioblastomas in von Hippel-Lindau disease. J Neurosurg. 2014;120(5):1055–1062.
- Dollfus H, Massin P, Taupin P, et al. Retinal hemangioblastoma in von Hippel-Lindau disease: a clinical and molecular study. Invest Ophthalmol Vis Sci. 2002;43(9):3067–3074.
- Kwon T, Jeong IG, Pak S, et al. Renal tumor size is an independent prognostic factor for overall survival in von Hippel-Lindau disease. J Cancer Res Clin Oncol. 2014;140(7):1171–1177.
- Jimenez C, Cabanillas ME, Santarpia L, et al. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab. 2009;94(2):386–391.
- Maher ER, Neumann HP, Richard S. Von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617–623.
- Kim HJ, Butman JA, Brewer C, et al. Tumors of the endolymphatic sac in patients with von Hippel-Lindau disease: implications for their natural history, diagnosis, and treatment. J Neurosurg. 2005;102(3):503–512.
- Cox R, Vang R, Epstein JI. Papillary cystadenoma of the epididymis and broad ligament: morphologic and immunohistochemical overlap with clear cell papillary renal cell carcinoma. Am J Surg Pathol. 2014;38(5):713–718.
- Ben-Skowronek I, Kozaczuk S. Von Hippel-Lindau syndrome. Horm Res Paediatr. 2015;84(3):145–152.
- Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von Hippel-Lindau disease. Hum Mutat. 2010;31(5):521–537.
- Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet. 1994;3:1303–1308.
- Brauch H, Kishida T, Glavac D, et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet. 1995;95:551–556.
- Zbar B, Kishida T, Chen F, et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat. 1996;8(4):348–357.
- Garcia A, Matias-Guiu X, Cabezas R, et al. Molecular diagnosis of von Hippel-Lindau disease in a kindred with a predominance of familial phaeochromocytoma. Clin Endocrinol Oxford. 1997;46:359–363.
- Mulvihill JJ, Ferrell RE, Carty SE, et al. Familial pheochromocytoma due to mutant von Hippel-Lindau disease gene. Arch Intern Med. 1997;157:1390–1391.
- Bender BU, Eng C, Olschewski M, et al. VHL c.505T>C mutation confers a high age-related penetrance but no increased overall mortality. J Med Genet. 2001;38:508–514.
- Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet. 2002;32:614–621.
- Lonser RR, Glenn GM, Walther M, et al. Von Hippel-Lindau disease. Lancet. 2003;361:2059–2067.
- Shuin T, Yamasaki I, Tamura K, et al. Von Hippel-Lindau disease: molecular pathological basis, clinical criteria, genetic testing, clinical features of tumors and treatment. Jpn J Clin Oncol. 2006;36:337–343.
- Zatyka M, da Silva NF, Clifford SC, et al. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res. 2002;1,62(13):3803–3811.
- MRC-Holland [https://www.mlpa.com/]. MRC-Holland; [cited 2007 Jun 28]. Available from: https://www.mlpa.com/WebForms/WebFormProductDetails.aspx?Tag=_tz2fAPIAupKyMjaDF-E-t9bmuxqlhe_Lgqfk8Hkjuss.&ProductOID=_P3G8NHKhaiY
- Ensembl genome browser 90 [www.ensembl.org/]. Ensembl; [cited 2017 Aug 29]. Available from: http://www.ensembl.org/Homo_sapiens/Transcript/Summary?db=core;g=ENSG00000134086;r=3:10141008-10152220;t=ENST00000256474
- LOVD - An Open Source DNA variation database system [www.lovd.nl/]. Leiden Open Variation Database 3.0; [cited 2017 Aug 29]. Available from: https://databases.lovd.nl/shared/view/VHL
- National Center for Biotechnology Information [https://www.ncbi.nlm.nih.gov/]. USA: National Center for Biotechnology Information; [cited 2017 Aug 29]. Available from: https://www.ncbi.nlm.nih.gov/clinvar/?term=VHL%5Bgene%5D
- Richards S, Aziz N, Bale S, et al. ACMG standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Gened Med. 2015;17(5):405–424.
- Ong KR, Woodward ER, Killick P, et al. Genotype–phenotype correlations in von Hippel-Lindau disease. Hum Mutat. 2007;28(2):143–149.
- Maher ER, Webster AR, Richards FM, et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet. 1996;33(4):328–332.
- Ruiz-Llorente S, Bravo J, Cebrián A, et al. Genetic characterization and structural analysis of VHL Spanish families to define genotype–phenotype correlations. Hum Mutat. 2004;23(2):160–169.
- Zhang M, Wang J, Jiang J, et al. Von Hippel-Lindau disease type 2 in a Chinese family with a VHL p.W88X truncation. Endocrine. 2015;48(1):83–88.
- Haase VH. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease. Kidney Int. 2006;69(8):1302–1307.
- Cho HJ, Ki CS, Kim JW. Improved detection of germline mutations in Korean VHL patients by multiple ligation-dependent probe amplification analysis. J Korean Med Sci. 2009;24(1):77–83.
- Coppin L, Grutzmacher C, Crépin M, et al. VHL mosaicism can be detected by clinical next-generation sequencing and is not restricted to patients with a mild phenotype. Eur J Hum Genet. 2014;22(9):1149–1152.
- Feldman DE, Thulasiraman V, Ferreyra RG, et al. Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC. Mol Cell. 1999;4(6):1051–1061.
- UCSC Genome Browser Home [https://genome.ucsc.edu/]. University of California Santa Cruz UCSC; [cited 2017 Aug 29]. Available from: https://genome.ucsc.edu/cgi-bin/hgBlat
- Emmrich S, Streltsov A, Schmidt F, et al. LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia. Mol Cancer. 2014;13:171.
- Bachurska S, Staykov D, Belovezhdov V, et al. Bilateral pheochromocytoma/intra-adrenal paraganglioma in von Hippel-Lindau patient causing acute myocardial infarction. Pol J Pathol. 2014;1(1):78–82.